513 related articles for article (PubMed ID: 1314653)
1. Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts.
Comess KM; Burstyn JN; Essigmann JM; Lippard SJ
Biochemistry; 1992 Apr; 31(16):3975-90. PubMed ID: 1314653
[TBL] [Abstract][Full Text] [Related]
2. Chemical and biological studies of the major DNA adduct of cis-diamminedichloroplatinum(II), cis-[Pt(NH3)2(d(GpG]], built into a specific site in a viral genome.
Naser LJ; Pinto AL; Lippard SJ; Essigmann JM
Biochemistry; 1988 Jun; 27(12):4357-67. PubMed ID: 3166983
[TBL] [Abstract][Full Text] [Related]
3. RNA polymerases react differently at d(ApG) and d(GpG) adducts in DNA modified by cis-diamminedichloroplatinum(II).
Corda Y; Anin MF; Leng M; Job D
Biochemistry; 1992 Feb; 31(7):1904-8. PubMed ID: 1536834
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin.
Donahue BA; Augot M; Bellon SF; Treiber DK; Toney JH; Lippard SJ; Essigmann JM
Biochemistry; 1990 Jun; 29(24):5872-80. PubMed ID: 2383564
[TBL] [Abstract][Full Text] [Related]
5. Single d(GpG)/cis-diammineplatinum(II) adduct-induced inhibition of DNA polymerization.
Suo Z; Lippard SJ; Johnson KA
Biochemistry; 1999 Jan; 38(2):715-26. PubMed ID: 9888812
[TBL] [Abstract][Full Text] [Related]
6. Effect of single DNA lesions on in vitro replication with DNA polymerase III holoenzyme. Comparison with other polymerases.
Belguise-Valladier P; Maki H; Sekiguchi M; Fuchs RP
J Mol Biol; 1994 Feb; 236(1):151-64. PubMed ID: 8107100
[TBL] [Abstract][Full Text] [Related]
7. Mutagenic and genotoxic effects of DNA adducts formed by the anticancer drug cis-diamminedichloroplatinum(II).
Yarema KJ; Lippard SJ; Essigmann JM
Nucleic Acids Res; 1995 Oct; 23(20):4066-72. PubMed ID: 7479066
[TBL] [Abstract][Full Text] [Related]
8. Spectrum of DNA--platinum adduct recognition by prokaryotic and eukaryotic DNA-dependent RNA polymerases.
Corda Y; Job C; Anin MF; Leng M; Job D
Biochemistry; 1993 Aug; 32(33):8582-8. PubMed ID: 7689335
[TBL] [Abstract][Full Text] [Related]
9. DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II).
Bellon SF; Coleman JH; Lippard SJ
Biochemistry; 1991 Aug; 30(32):8026-35. PubMed ID: 1868076
[TBL] [Abstract][Full Text] [Related]
10. Polymerization by DNA polymerase eta is blocked by cis-diamminedichloroplatinum(II) 1,3-d(GpTpG) cross-link: implications for cytotoxic effects in nucleotide excision repair-negative tumor cells.
Chijiwa S; Masutani C; Hanaoka F; Iwai S; Kuraoka I
Carcinogenesis; 2010 Mar; 31(3):388-93. PubMed ID: 20015866
[TBL] [Abstract][Full Text] [Related]
11. Instability of the monofunctional adducts in cis-[Pt(NH3)2(N7-N-methyl-2-diazapyrenium)Cl](2+)-modified DNA: rates of cross-linking reactions in cis-platinum-modified DNA.
Payet D; Gaucheron F; Sip M; Leng M
Nucleic Acids Res; 1993 Dec; 21(25):5846-51. PubMed ID: 8290343
[TBL] [Abstract][Full Text] [Related]
12. Bending studies of DNA site-specifically modified by cisplatin, trans-diamminedichloroplatinum(II) and cis-[Pt(NH3)2(N3-cytosine)Cl]+.
Bellon SF; Lippard SJ
Biophys Chem; 1990 Apr; 35(2-3):179-88. PubMed ID: 2397272
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and characterization of trans-[Pt(NH3)2Cl2] adducts of d(CCTCGAGTCTCC).d(GGAGACTCGAGG).
Lepre CA; Chassot L; Costello CE; Lippard SJ
Biochemistry; 1990 Jan; 29(3):811-23. PubMed ID: 2159792
[TBL] [Abstract][Full Text] [Related]
14. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation.
Fichtinger-Schepman AM; van der Veer JL; den Hartog JH; Lohman PH; Reedijk J
Biochemistry; 1985 Jan; 24(3):707-13. PubMed ID: 4039603
[TBL] [Abstract][Full Text] [Related]
15. Formation of cis-diamminedichloroplatinum(II) 1,2-intrastrand cross-links on DNA is flanking-sequence independent.
Burstyn JN; Heiger-Bernays WJ; Cohen SM; Lippard SJ
Nucleic Acids Res; 2000 Nov; 28(21):4237-43. PubMed ID: 11058123
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic studies of a novel class of trisubstituted platinum(II) antitumor agents.
Hollis LS; Sundquist WI; Burstyn JN; Heiger-Bernays WJ; Bellon SF; Ahmed KJ; Amundsen AR; Stern EW; Lippard SJ
Cancer Res; 1991 Apr; 51(7):1866-75. PubMed ID: 2004370
[TBL] [Abstract][Full Text] [Related]
17. Effects of DNA adduct structure and distribution on the mutagenicity and genotoxicity of two platinum anticancer drugs.
Yarema KJ; Wilson JM; Lippard SJ; Essigmann JM
J Mol Biol; 1994 Mar; 236(4):1034-48. PubMed ID: 8120885
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and 1H NMR spectroscopic characterization of trans-[Pt(NH3)2[d(ApGpGpCpCpT)-N7-A(1),N7-G(3)]].
Lepre CA; Strothkamp KG; Lippard SJ
Biochemistry; 1987 Sep; 26(18):5651-7. PubMed ID: 3676275
[TBL] [Abstract][Full Text] [Related]
19. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts.
Vaisman A; Lim SE; Patrick SM; Copeland WC; Hinkle DC; Turchi JJ; Chaney SG
Biochemistry; 1999 Aug; 38(34):11026-39. PubMed ID: 10460158
[TBL] [Abstract][Full Text] [Related]
20. Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication.
Heiger-Bernays WJ; Essigmann JM; Lippard SJ
Biochemistry; 1990 Sep; 29(36):8461-6. PubMed ID: 2174701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
